Didanosine: Difference between revisions
imported>David E. Volk (New page: {{subpages}} [[Image:Didanosine structure.jpg|right|thumb|150px|{{#ifexist:Template:Didanosine structure.jpg/credit|{{Didanosine structure.jpg/credit}}<br/>|}}Didanosine, a nucleoside reve...) |
imported>David E. Volk (typo) |
||
| Line 2: | Line 2: | ||
[[Image:Didanosine structure.jpg|right|thumb|150px|{{#ifexist:Template:Didanosine structure.jpg/credit|{{Didanosine structure.jpg/credit}}<br/>|}}Didanosine, a nucleoside reverse transcriptase inhibitor.]] | [[Image:Didanosine structure.jpg|right|thumb|150px|{{#ifexist:Template:Didanosine structure.jpg/credit|{{Didanosine structure.jpg/credit}}<br/>|}}Didanosine, a nucleoside reverse transcriptase inhibitor.]] | ||
'''Didanosine''' ('''DDI'''), or '''dideoxyinosine''', is a potent [[HIV]]-1 [[reverse transcriptase inhibitor]] that also acts as a viral [[DNA]] chain terminator. Treatment with DDI after long-term [[AZT]] treatment has been | '''Didanosine''' ('''DDI'''), or '''dideoxyinosine''', is a potent [[HIV]]-1 [[reverse transcriptase inhibitor]] that also acts as a viral [[DNA]] chain terminator. Treatment with DDI after long-term [[AZT]] treatment has been beneficial. Didanosine is unusual among nucleoside analogs because it does not contain a regular base or regular sugar, but instead contains hypoxanthine attached to a dideoxy sugar. The absence of a 3'-hydroxy group on the sugar prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. DDI is metabolized to dideoxyadenosine triphosphate (ddATP), its putative active metabolite that competes with dATP. It is often taken with antacids because its stability is low under acidic conditions. It is sold under the brand names '''Videx''' and '''Videx EC'''. Possible toxic side effects including [[diarrhea]], [[hepatic dysfunction|liver dysfunction]], | ||
[[hyperuricemia]], [[pancreatitis]] and peripheral [[neuropathy]]. | [[hyperuricemia]], [[pancreatitis]] and peripheral [[neuropathy]]. | ||
Revision as of 16:39, 31 January 2008
Didanosine (DDI), or dideoxyinosine, is a potent HIV-1 reverse transcriptase inhibitor that also acts as a viral DNA chain terminator. Treatment with DDI after long-term AZT treatment has been beneficial. Didanosine is unusual among nucleoside analogs because it does not contain a regular base or regular sugar, but instead contains hypoxanthine attached to a dideoxy sugar. The absence of a 3'-hydroxy group on the sugar prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. DDI is metabolized to dideoxyadenosine triphosphate (ddATP), its putative active metabolite that competes with dATP. It is often taken with antacids because its stability is low under acidic conditions. It is sold under the brand names Videx and Videx EC. Possible toxic side effects including diarrhea, liver dysfunction, hyperuricemia, pancreatitis and peripheral neuropathy.
Its IUPAC chemical name is 9-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one and its chemical formula is C10H12N4O3 (MW 236.2273).
External Links
- Didanosine - FDA approved drug information (drug label) from DailyMed (U.S. National Library of Medicine).